Goyal Lajya Devi, Kaur Balpreet, Goyal Gitanjali, Rajora Parveen
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Punjab, India.
Department of Biochemistry, Guru Gobind Singh Medical College and Hospital, Punjab, India.
J Reprod Infertil. 2021 Oct-Dec;22(4):267-273. doi: 10.18502/jri.v22i4.7652.
Malignant ovarian germ cell tumors (MOGCTs) are rare female cancers, constituting up to 10% of ovarian cancers. Dysgerminoma is the most common histological variant. Surgical removal of the tumor with optimal debulking is the treatment of choice. Multidrug chemotherapy following surgery offers high remission rates. Considering the prevalence of these tumors in adolescent and young females, fertility-sparing treatment is of paramount importance.
The data of all patients with ovarian malignancy admitted at a tertiary-care-teaching hospital from September 2009-March 2019 were analyzed. Ten patients of MOGCTs were treated in this period. The clinical features, radiological and biochemical findings, and management and treatment outcome were evaluated.
The median age of patients was 23 years. Histological subtypes included immature teratoma (n=3), endodermal sinus tumor (n=4), and dysgerminoma (n=3). Tumor markers namely AFP, βHCG, and LDH increased in all except the patients with immature teratoma. Two patients with dysgerminoma were in the second trimester of pregnancy. All patients except one underwent surgery followed by BEP chemotherapy. Two patients had developed metastasis within six months of treatment and died. In seven patients, no evidence of disease was reported till date.
Management of antenatal patients with dysgerminoma by surgery followed by BEP chemotherapy has favorable prognosis. Fertility-sparing surgery with adjuvant chemotherapy offers great advantage in young girls. However, risk stratification based on prognostic factors should be implemented in order to individualize the treatment for achieving higher survival rates. The option for oocyte-cryopreservation prior to surgery must be discussed with patients desiring future fertlity.
恶性卵巢生殖细胞肿瘤(MOGCTs)是罕见的女性癌症,占卵巢癌的比例高达10%。无性细胞瘤是最常见的组织学亚型。手术切除肿瘤并达到最佳减瘤效果是首选治疗方法。术后多药化疗缓解率高。鉴于这些肿瘤在青少年和年轻女性中的发病率,保留生育功能的治疗至关重要。
分析了2009年9月至2019年3月在一家三级教学医院收治的所有卵巢恶性肿瘤患者的数据。在此期间治疗了10例MOGCTs患者。评估了临床特征、影像学和生化检查结果以及治疗和治疗效果。
患者的中位年龄为23岁。组织学亚型包括未成熟畸胎瘤(n = 3)、内胚窦瘤(n = 4)和无性细胞瘤(n = 3)。除未成熟畸胎瘤患者外,所有患者的肿瘤标志物甲胎蛋白(AFP)、β人绒毛膜促性腺激素(βHCG)和乳酸脱氢酶(LDH)均升高。两名无性细胞瘤患者处于妊娠中期。除一名患者外,所有患者均接受了手术,随后进行了博来霉素、依托泊苷和顺铂(BEP)化疗。两名患者在治疗后六个月内发生转移并死亡。截至目前,七名患者未报告疾病证据。
产前无性细胞瘤患者通过手术联合BEP化疗进行治疗,预后良好。保留生育功能的手术联合辅助化疗对年轻女孩具有很大优势。然而,应根据预后因素进行风险分层,以便个体化治疗以提高生存率。对于希望未来生育的患者,必须在手术前与其讨论卵母细胞冷冻保存的选择。